

Drug Monograph

Drug/Drug **Avar™ (sulfacetamide sodium, sulfur) Cleansing Pad /**
 Class: **bacteriostatic agent**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each pad of Avar™ is coated with a cleanser-based formulation. Each gram of solution contains 95 mg of sodium sulfacetamide and 50 mg of colloidal sulfur in a vehicle.

Manufacturer: MISSION PHARMACAL COMPANY
San Antonio, TX 78230 1355

Indications: Avar™ is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

Costs: \$7.33 per cleansing pad of Avar™ WholesaleAcquisitionCost

Summary of Findings: The MO HealthNet Division recommends prior authorization status for this product.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Non-Preferred Agent
 Appropriate Indications No PA Required

Prepared By: Katie Wilbers, PharmD
 Date: February 27, 2014